Pricing
  1. JP-listed companies
  2. ADR120S, Inc.
  3. Financials
  4. Revenue growth (%)

ADR120S, Inc.【JP:3750】

Market cap
¥7.9B
P/E ratio
110.7x
Saitori Cell Research Institute develops regenerative cell therapies and medical devices while also investing in real estate projects through seven subsidiaries.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 2025-92.2+238.36%
Mar 31, 2024-27.2-144.97%
Mar 31, 202360.6-1694.21%
Mar 31, 2022-3.8-121.58%
Mar 31, 202117.6-145.54%
Mar 31, 2020-38.7-114.40%
Mar 31, 2019268.6-433.16%
Mar 31, 2018-80.6-26103.23%
Mar 31, 20170.3-100.91%
Mar 31, 2016-34.1-321.18%
Mar 31, 201515.4-70.57%
Mar 31, 201452.5-357.58%
Mar 31, 2013-20.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)